Results 111 to 120 of about 84,691 (282)

Case Report: Myeloid neoplasms with the t(3;12)(q26.2;p13.1)/MECOM-ETV6 translocation: report of two new cases and review of the literature

Frontiers in Oncology
The MECOM (MDS1 and EVI1 complex locus) gene, located at 3q26.2, encodes an oncogenic transcription factor implicated in multiple signaling pathways.
Soumya Mikkilineni, Juan Pablo Pineda-Reyes, Lindsay Wilde, Andres Ferber, Zi-Xuan Wang, Stephen Peiper, Guldeep Uppal, Jerald Gong, Jinglan Liu   +8 more
doaj   +1 more source

Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases. [PDF]

An Bras Dermatol, 2023
de Souza PK, Amorim RO, Sousa LS, Batista MD.   +3 more
europepmc   +1 more source

Racial and ethnic disparities in hematologic malignancies

, 2017
Racial and ethnic disparities in patients with solid malignancies have been well documented. Less is known about these disparities in patients with hematologic malignancies. With the advent of novel chemotherapeutics and targeted molecular, cellular, and
Stephanie J. Lee, Kedar Kirtane
core   +1 more source

Turning Unpredictable Biomolecule Adsorption to Controlled Corona Formation: Focus on Carbon Nanomaterials

Advanced Materials, EarlyView.
Controlling the protein corona formation onto carbon nanomaterials (CNMs) enhances their functionalities as platforms for cancer theranostics. Here, we reviewed the effects of the intrinsic and acquired properties of CNMs on protein corona formation, the consequent biological and toxicological outcomes, and the strategies to reshape corona formation ...
Yajuan Zou, Yalei Hu, Jie Yu, Naoki Komatsu, Yuta Nishina, Alberto Bianco   +5 more
wiley   +1 more source

Colorectal Carcinoma—An Anomalous Trigger of Adult Hemophagocytic Lymphohistiocytosis

Journal of Investigative Medicine High Impact Case Reports
Hemophagocytic lymphohistiocytosis (HLH) is a rare but often fatal condition characterized by a hyperinflammatory immune response leading to multiorgan failure. It is predominantly observed in the pediatric population and can be classified as familial or
Ameish Govindarajan MD, Frederick Venter MD, Akriti Chaudhry MD, Harsimranjit Kaur MD, Everardo Cobos MD, Greti Petersen MD   +5 more
doaj   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

Participation and Influencing Factors in the Decision-Making of Life-Sustaining Treatment: A Focus on Deceased Patients with Hematologic Neoplasms. [PDF]

J Hosp Palliat Care, 2023
Jang JE, Ryu JM, Heo MH, Kwon DE, Seo JY, Kim DY.   +5 more
europepmc   +1 more source

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source